
Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.
Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options.
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the impact of lenvatinib in differentiated thyroid cancer. Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options. He adds that while lenvatinib is considered the standard of care in thyroid cancer, these treatments will only function in any given patient for a limited amount of time.






